{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:11:31Z","timestamp":1788293491268,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Clinically Important Deterioration (CID) is a novel composite measure to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined the performance and utility of CID in assessing the effect of inhaled corticosteroids (ICS) in COPD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This <jats:italic>post-hoc<\/jats:italic> analysis of four budesonide\/formoterol (BUD\/FORM) studies comprised 3576 symptomatic moderate-to-very-severe COPD patients with a history of exacerbation. Analysis of time to first CID event (exacerbation, deterioration in forced expiratory volume in 1 second [FEV<jats:sub>1<\/jats:sub>] or worsening St George\u2019s Respiratory Questionnaire [SGRQ] score) was completed using Cox proportional hazards models.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The proportion of patients with \u22651 CID in the four studies ranged between 63 and 77% and 69\u201384% with BUD\/FORM and FORM, respectively, with an average 25% reduced risk of CID with BUD\/FORM. All components contributed to the CID event rate. Experiencing a CID during the first 3\u2009months was associated with poorer outcomes (lung function, quality of life, symptoms and reliever use) and increased risk of later CID events. The effect of BUD\/FORM versus FORM in reducing CID risk was positively associated with the blood eosinophil count.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our findings suggest that BUD\/FORM offers protective effects for CID events compared with FORM alone, with the magnitude of the effect dependent on patients\u2019 eosinophil levels. CID may be an important tool for evaluation of treatment effect in a complex, multifaceted, and progressive disease like COPD, and a valuable tool to allow for shorter and smaller future outcome predictive trials in early drug development.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-1280-y","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T17:03:01Z","timestamp":1578675781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-2478","authenticated-orcid":false,"given":"Mona","family":"Bafadhel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wessman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Fager\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int J COPD. 2016;11:1413\u201324.","journal-title":"Int J COPD"},{"key":"1280_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12931-018-0928-3","volume":"19","author":"IP Naya","year":"2018","unstructured":"Naya IP, Tombs L, Muellerova H, Compton C, Jones PW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19:222.","journal-title":"Respir Res"},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/COPD.S133307","volume":"12","author":"AR Anzueto","year":"2017","unstructured":"Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R. The effect of indacaterol\/glycopyrronium versus tiotropium or salmeterol\/fluticasone on the prevention of clinically important deterioration in COPD. Int J COPD. 2017;12:1325\u201337.","journal-title":"Int J COPD"},{"key":"1280_CR4","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","volume":"33","author":"MR Maleki-Yazdi","year":"2017","unstructured":"Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33:2188\u201399.","journal-title":"Adv Ther"},{"key":"1280_CR5","first-page":"A3042","volume":"197","author":"I Naya","year":"2018","unstructured":"Naya I, Driessen MT, Paly V, Gunsoy N, Risebrough N, Briggs A, Ismaila AS. Long-term consequences of clinically important deterioration in patients with chronic obstructive pulmonary disease treated with twice-daily inhaled corticosteroid\/long-acting beta2-agonist therapy: results from the TORCH study. Am J Respir Crit Care Med. 2018;197:A3042.","journal-title":"Am J Respir Crit Care Med"},{"key":"1280_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12931-017-0583-0","volume":"18","author":"D Singh","year":"2017","unstructured":"Singh D, D'Urzo AD, Chuecos F, Munoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium\/formoterol. Respir Res. 2017;18:106.","journal-title":"Respir Res"},{"key":"1280_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","volume":"6","author":"M Bafadhel","year":"2018","unstructured":"Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117\u201326.","journal-title":"Lancet Respir Med"},{"key":"1280_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747\u201358.","journal-title":"Lancet Respir Med"},{"key":"1280_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","volume":"69","author":"SI Rennard","year":"2009","unstructured":"Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549\u201365.","journal-title":"Drugs"},{"key":"1280_CR10","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","volume":"68","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68:1975\u20132000.","journal-title":"Drugs"},{"key":"1280_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","volume":"106","author":"A Sharafkhaneh","year":"2012","unstructured":"Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106:257\u201368.","journal-title":"Respir Med"},{"key":"1280_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.rmed.2017.09.002","volume":"132","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, Tashkin DP, Skarby T, Jorup C, Sandin K, Greenwood M, Pemberton K, Trudo F. Effect of budesonide\/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (revealing the impact of Symbicort in reducing exacerbations in COPD) study. Respir Med. 2017;132:31\u201341.","journal-title":"Respir Med"},{"key":"1280_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12931-016-0356-1","volume":"17","author":"AL Martin","year":"2016","unstructured":"Martin AL, Marvel J, Fahrbach K, Cadarette SM, Wilcox TK, Donohue JF. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. Respir Res. 2016;17:40.","journal-title":"Respir Res"},{"key":"1280_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"},{"key":"1280_CR15","volume-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2019","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2019."},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12931-018-0830-z","volume":"19","author":"AR Anzueto","year":"2018","unstructured":"Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA. Indacaterol\/glycopyrronium versus salmeterol\/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19:121.","journal-title":"Respir Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-1280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-020-1280-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-1280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T01:16:28Z","timestamp":1610154988000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-1280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-1280-y","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"26 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB has received honoraria and travel expenses from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline. DS has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance and Verona. CRJ has received speaking and advisory fees and fees for attending advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Menarini, Mundipharma and Sanofi Regeneron. SP and TB are employees of StatMind, which received funding from AstraZeneca to complete the statistical analyses. PW and MF are full-time employees of AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}